STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, announced that CEO Michael A. Metzger will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 10:30 a.m. PT/ 1:30 p.m. ET. Interested parties can access a live webcast of the fireside chat through the Investor section of Syndax's website, where a replay will also be available temporarily.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+0.80% News Effect

On the day this news was published, SNDX gained 0.80%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 10:30 a.m. PT/ 1:30 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

Cision View original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-43rd-annual-jp-morgan-healthcare-conference-302343500.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When is Syndax (SNDX) presenting at the 2025 J.P. Morgan Healthcare Conference?

Syndax (SNDX) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. PT/ 1:30 p.m. ET.

How can investors watch Syndax's (SNDX) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live webcast of Syndax's presentation through the Investor section of the company's website at www.syndax.com, where a replay will also be available for a time.

Who will represent Syndax (SNDX) at the 2025 J.P. Morgan Healthcare Conference?

Michael A. Metzger, Chief Executive Officer of Syndax, will represent the company at the conference.

What type of presentation will Syndax (SNDX) give at the J.P. Morgan Healthcare Conference?

Syndax will participate in a fireside chat format presentation at the conference.
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Latest SEC Filings

SNDX Stock Data

1.72B
85.79M
1.29%
120.98%
24.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK